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Key points: 
1. Uncoupling of G6b-B from Shp1 and Shp2 results in severe macrothrombocytopenia 
and aberrant platelet function. 
2. G6b-B inhibits CLEC-2 signaling primarily through the protein-tyrosine phosphatase 
Shp2.   
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Abstract 
The immunoreceptor tyrosine-based inhibitory motif (ITIM)-containing receptor G6b-B has 
emerged as a key regulator of platelet homeostasis.  However, it remains unclear how it 
mediates its effects.  Tyrosine phosphorylation of the ITIM and immunoreceptor tyrosine-
based switch motif (ITSM) within the cytoplasmic tail of G6b-B provides a docking site for 
SH2 domain-containing protein-tyrosine phosphatases Shp1 and Shp2, which are also 
critical regulators of platelet production and function.  In this study, we investigate the 
physiological consequences of uncoupling G6b-B from Shp1 and Shp2.  To address this, 
we generated a transgenic mouse model expressing a mutant form of G6b-B in which 
tyrosine (Y) residues 212 and 238 within the ITIM and ITSM were mutated to phenylalanine 
(F), respectively.  Mice homozygous for the mutation (G6b-B diY/F) were 
macrothrombocytopenic, due to a reduction in platelet production, had large clusters of 
megakaryocytes and myelofibrosis at sites of hematopoiesis, similar to that observed in 
G6b knockout (G6b KO) mice.  Platelets from G6b-B diY/F mice were hypo-responsive to 
collagen, due to a significant reduction in expression of the immunoreceptor tyrosine-based 
activation motif (ITAM)-containing collagen receptor complex GPVI-FcR -chain, and 
thrombin, that could be partially rescued by co-stimulating the platelets with ADP.  In 
contrast, platelets from G6b-B diY/F, G6b KO and megakaryocyte-specific Shp2 KO mice 
were hyper-responsive to antibody-mediated cross-linking of the hemi-ITAM-containing 
podoplanin receptor CLEC-2, suggesting that G6b-B inhibits CLEC-2-mediated platelet 
activation through Shp2.  Findings from this study demonstrate that G6b-B must engage 
with Shp1 and Shp2 in order to mediate its regulatory effects on platelet homeostasis. 
4 
 
Introduction 
Platelets are small fragments of megakaryocytes (MKs) that play a critical role in 
thrombosis, hemostasis and maintenance of vascular integrity.1,2  They do so by adhering 
to exposed extracellular matrix proteins at sites of vascular injury, where they become 
activated and form a hemostatic plug, preventing excessive blood loss and stimulating 
wound repair.  The mechanisms required to maintain hemostasis also facilitate the 
formation of occlusive thrombi, leading to ischemia in acute coronary heart disease and 
stroke, two of the leading causes of death worldwide.  It is therefore critical to understand 
the molecular mechanisms controlling platelet production and function, in order to devise 
new and improved ways of regulating these processes.    
 Immunoreceptor tyrosine-based inhibition motif (ITIM)-containing receptors are 
important inhibitors of platelet activation.3  They function through a conserved intracellular 
ITIM (consensus sequence: I/V/LxYxxL/V),4 usually in tandem with another ITIM or an 
immunoreceptor tyrosine-based switch motif (ITSM, consensus sequence: TxYxxV/I).5  
Tyrosine residues within the ITIM and ITSM are phosphorylated by Src family kinases 
(SFKs), providing docking sites for the structurally-related Src homology 2 (SH2) domain-
containing protein-tyrosine phosphatases (PTPs) Shp1 and Shp2.4  This interaction 
predominantly inhibits signaling from immunoreceptor tyrosine-based activation motif 
(ITAM)-containing receptors (consensus sequence: YxxI/Lx6-12YxxI/L).  Characterization of 
knockout (KO) mouse models has also revealed ITIM-containing receptors as regulators of 
platelet number.6-8 
G6b-B is a type I transmembrane glycoprotein, consisting of a single extracellular 
immunoglobulin-like variable-type domain, a transmembrane region and a cytoplasmic tail.  
The cytoplasmic tail contains a juxtamembrane proline rich region (PRR), an ITIM and a C-
terminal ITSM.  An inhibitory role for G6b-B in regulating ITAM-mediated platelet activation 
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was shown using G6b-B-deficient mice (G6b-/-, referred to as G6b KO), and G6b-B-GPVI 
double-heterozygous mice (G6b+/-Gp6+/-).6  Unexpectedly, G6b KO mice also exhibited 
severe macrothrombocytopenia and aberrant proplatelet formation.  Concomitant deletion 
of GPVI and CLEC-2 failed to fully rescue the G6b KO phenotype, suggesting other 
physiological functions of G6b-B that go beyond inhibiting ITAM receptor signaling.6  
Intriguingly, patients lacking G6b-B exhibit a similar phenotype to that of G6b KO mice, 
including macrothrombocytopenia, megakaryocyte clusters in the bone marrow and 
myelofibrosis (Hofmann et al. co-submitted).9  Indeed, recent findings using a humanized 
G6b-B mouse model confirmed that human and mouse G6b-B perform analogous 
physiological functions (Hofmann et al. co-submitted). 
G6b-B is thought to mediate its functions through association with Shp1 and 
Shp2.6,10  Activation of Shp phosphatases depends upon phosphopeptide binding of the N-
terminal SH2 domain, which normally blocks access of substrates to the PTP catalytic 
site.11  MK-specific Shp2, and to a lesser extent Shp1, KO mouse models (Ptpn11fl/fl;PF4-
Cre+ and Ptpn6fl/fl;Pf4-Cre+, referred to as Shp2 KO and Shp1 KO, respectively), phenocopy 
multiple features of G6b KO mice.12  However, Shp1/Shp2 conditional double-KO mice 
(Ptpn6fl/fl;Ptpn11fl/fl;Pf4-Cre+, referred to as Shp1/Shp2 DKO) exhibited a more severe 
phenotype than G6b KO mice,12,13 demonstrating additional roles of Shp1 and Shp2 in MKs 
and platelets. 
The aim of this study was to determine the role of G6b-B-mediated 
compartmentalization of Shp1 and Shp2 in regulating platelet production and function.  To 
address this, we generated and characterized a novel knock-in (KI) mouse model, in which 
tyrosine (Y) residues 212 and 238, within the ITIM and ITSM of G6b-B were mutated to 
phenylalanine (F), respectively.  Mice homozygous for these loss-of-function mutations 
(G6bdiYF/diYF, referred to as G6b-B diY/F) were severely macrothrombocytopenic and 
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showed a significant downregulation of the ITAM-containing GPVI-FcR -chain complex, 
highlighting the critical role of Shp1 and Shp2 recruitment to G6b-B for it to mediate its 
biological effects.  We also demonstrate that the inhibitory effect of G6b-B on CLEC-2 
signaling is primarily mediated by Shp2, as well as providing structural insights into the 
interaction between phosphorylated G6b-B and Shp2. 
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Materials and methods 
Antibodies and reagents 
FITC-conjugated P-selectin, GPVI, GPIb and 2, and R-phycoerythrin (PE)-conjugated 
JON/A antibodies were from Emfret Analytics (Eibelstadt, Germany); PE-conjugated anti-
IIb antibody from BD Biosciences (Oxford, UK); fibrinogen-488 and phalloidin-488 from 
Thermo Fisher (Loughborough, UK); rat anti-mouse CLEC-2 antibody and IgG2B isotype 
control antibody from Serotec (Oxford, UK) and Alexa488-conjugated goat anti-rat antibody 
from Life Technologies (Paisley, UK).  G6b-B specific antibodies were raised as previously 
described.6  For immunoblotting, anti-Shp1 and anti-Shp2 antibodies were from Santa Cruz 
Biotechnology (Dallas, TX, USA); anti-phosphotyrosine (p-Tyr); FcR -chain and PAR4 
antibodies from Merck Millipore (Nottingham, UK); Src phosphotyrosine-418 (Src p-Tyr418) 
from Life Technologies (Loughborough, UK) and Syk phosphotyrosine-525/26 (Syk p-
Tyr525/526) from Cell Signaling Technology (Hitchin, UK).  All other reagents were from 
Sigma-Aldrich (Poole, UK).  
Mice 
The G6b-B diY/F KI mouse model was generated as outlined in the supplementary methods 
(Taconic Biosciences, Cologne, Germany).  G6b constitutive KO and conditional Shp1 and 
Shp2 KO mouse models, referred to as G6b KO, Shp1 KO and Shp2 KO, respectively, 
were generated as previously described. 6,12  Genotypes of litter matched control mice (WT) 
were G6b+/+, Ptpn6fl/fl;Pf4-Cre- and Ptpn11fl/fl;Pf4-Cre-.  All mouse models used in this study 
were on a C57BL/6 background.  Procedures were undertaken with UK Home Office 
approval, in accordance with the Animals (Scientific Procedures) Act of 1986. 
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Statistical analysis 
All data is presented as mean ± standard error of the mean (SEM), unless stated otherwise.  
Statistical significance was analyzed either by Student’s t-test or two-way ANOVA, followed 
by the indicated post hoc test, using GraphPad Prism 6 (GraphPad Software, Inc., La Jolla, 
CA), unless stated otherwise.   
Detailed descriptions of all other methods can be found in Supplementary Methods. 
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Results 
Verification of G6b-B diY/F mouse model 
To determine the physiological importance of the interaction between G6b-B-Shp1-Shp2 in 
platelet production and function, we generated a G6b-B diY/F mouse model (Figure S1) 
expressing a mutant form of G6b-B that is unable to engage with Shp1 or Shp2.  The 
specific abolition of Shp1 and Shp2 docking sites allowed for delineation of the importance 
of this binding event and downstream signaling, independent of other potential signaling 
events.  G6b-B diY/F mice were born at Mendelian frequencies (Table S1), were fertile and 
survived >25 weeks without any overt developmental or growth defects.  Both surface and 
total protein expression of G6b-B diY/F in platelets from KI mice was comparable to that of 
G6b-B in platelets from WT mice (Figure 1A, B).  As expected, neither Shp1 nor Shp2 co-
immunoprecipitated with G6b-B diY/F from resting or collagen-stimulated platelets (Figure 
1C), demonstrating that interactions between G6b-B-Shp1-Shp2 were indeed lost.  
Immunoprecipitation of Shp2 also confirmed absence of the interaction (Figure S2). 
Reduced platelet production in G6b-B diY/F mice 
G6b-B diY/F mice were severely macrothrombocytopenic, as observed in G6b KO mice.  
Platelet count was reduced by 76% and platelet volume increased by 36% in G6b-B diY/F 
mice, compared with WT mice (Table S2).  These changes were independent of age 
(Figure S3).   Increased platelet volume is frequently associated with immature platelets, 
which was confirmed by an increased proportion of reticulated platelets in G6b-B diY/F mice 
(Figure 2A).  Thrombocytopenia in these mice was not a consequence of reduced platelet 
lifespan, measured as the proportional slope to give the rate of clearance of biotinylated 
platelets from the circulation (Figure 2B).   
 As clearance was normal, reduced platelet counts had to be due to defects in 
production.  We therefore investigated platelet recovery following anti-GPIb antibody-
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mediated depletion (Figure 2Ci).  Proportional slopes for days 3-7 were calculated and 
compared for WT and G6b-B diY/F mice.  A four-fold reduction in the number of platelets 
produced per day was identified in G6b-B diY/F mice compared with WT mice (Figure 2Cii), 
suggesting aberrant platelet production by MKs.  This was supported by increased MK 
clusters and myelofibrosis in spleens and femurs, and an 86% increase in spleen:body 
weight ratio (Figure 2D).  MKs tended to be localized in distinct large clusters throughout 
the bone marrow and red pulp of spleens, similar to that observed in G6b-B-deficient 
patients (Hofmann et al, co-submitted).  Interestingly, lymphocyte counts were also 
increased in G6b-B diY/F mice, as observed in both patients and G6b KO mice, likely due 
to inflammation caused by the severe myelofibrosis. 
Increased bleeding is caused by aberrant platelet function in G6b-B diY/F mice 
A primary function of platelets is to prevent blood loss following injury.  We therefore 
investigated the effect of loss of G6b-B-Shp1-Shp2 interactions on hemostasis.  Overall, 
blood loss increased in both G6b-B diY/F and G6b KO mice, although for both genotypes 
there were mice with apparently normal bleeding (Figure 3A).  The probability of abnormal 
bleeding in GM mice was determined by modelling blood loss to a bimodal distribution.  The 
probability of abnormal bleeding in G6b-B diY/F mice was 0.47 [0.23, 0.72] (mean [95% CI]) 
and for G6b KO mice was 0.79 [0.49, 0.94].  Pairwise testing between the 3 groups 
(likelihood ratio test with no adjustment for multiple testing) indicated a clear difference 
between WT (probability of increased bleeding = 0) and both G6b-B diY/F (P = 0.0006) and 
G6b KO (P = 1.0 x 10-6) mice.  Although G6b-B diY/F mice had a lower probability of 
bleeding than G6b KO mice, the difference was less clear-cut (P = 0.071).  Since platelet 
counts must drop by more than 90% for defective hemostasis to be observed,14 aberrant 
platelet function is the most likely underlying explanation of this bleeding phenotype, 
warranting further investigation. 
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To determine the cause of platelet functional defects, we measured surface receptor 
expression levels in G6b-B diY/F mice by flow cytometry (Figure S4).  Expression of GPVI, 
the main receptor facilitating signaling in response to collagen, was reduced by 81%.  Only 
minor changes were observed in other platelet receptors: 22% reduction in the collagen 
integrin 2 subunit, 7% increase in the fibrinogen integrin IIb subunit and 20% reduction in 
CLEC-2 expression.  GPIb surface expression was unaltered.  Western blotting showed 
comparable expression levels of the receptors investigated by flow cytometry, and a small 
increase in the thrombin receptor PAR4 (Figure S5).  Interestingly, alterations in receptor 
levels did not fully correlate between G6b-B diY/F and G6b KO mice, GPIb levels were 
significantly reduced in G6b KO platelets,6 suggesting residual functional roles of G6b-B 
diY/F.  This may explain differences in bleeding distributions in G6b-B diY/F and G6b KO 
mice, described above.   
We next set out to identify how these changes in receptor expression affect platelet 
function.  Due to the severe thrombocytopenia of G6b-B diY/F mice, a flow cytometry-based 
assay was first used to assess platelet activation in whole blood.  P-selectin exposure and 
fibrinogen-binding were used as markers of -granule release and IIb3 integrin 
activation, respectively.  Not surprisingly, responses to the GPVI-specific agonist collagen-
related peptide (CRP) were significantly reduced in G6b-B diY/F platelets (Figure 3B).  
Neither was a consequence of reduced P-selectin or IIb3 expression (Figure S4, 5).  
Convulxin, a more potent GPVI agonist than CRP, induced higher levels of P-selectin 
exposure and fibrinogen-binding in G6b-B diY/F platelets, but still failed to reach levels 
observed in WT platelets (Figure 3B).  P-selectin exposure was marginally reduced in 
G6b-B diY/F platelets in response to antibody-mediated cross-linking of CLEC-2, whereas 
fibrinogen-binding was normal (Figure 3B).   
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No difference was observed between G6b-B diY/F and WT mice in response to ADP 
or the TxA2 analogue U46619, both of which elicited only weak responses when used either 
alone or in combination (Figure 3C).  However, P-selectin surface exposure was 
significantly reduced in G6b-B diY/F platelets in response to thrombin and PAR4 peptide 
(Figure 3Ci).  Fibrinogen-binding was normal in response to thrombin and reduced in 
response to PAR4 peptide (Figure 3Cii), presumably because thrombin also binds to GPIb 
and is a more potent agonist than PAR4 peptide.  Interestingly, P-selectin surface exposure 
was not rescued in G6b-B diY/F platelets co-stimulated with 10 M ADP and PAR4 peptide 
(Figure 3Di).  In contrast, IIb3 activation was increased to levels observed in WT mouse 
platelets (Figure 3Dii), suggesting a more severe impairment in -granule release than 
integrin activation.  Comparable results were obtained for most agonists using washed 
platelets at a normalized count (2 × 107/mL) (Figure S6).  Interestingly G6b-B diY/F 
platelets showed increased CLEC-2 antibody-mediated P-selectin exposure and unaltered 
PAR4 peptide-stimulated fibrinogen binding compared to WT, both of which were 
significantly reduced in whole blood activations.  Increased relative levels of secondary 
activators, such as ADP and TxA2, which are known to be essential for CLEC-2 signaling,15 
and contributed to the PAR4-mediated defect (Figure 3D), are likely responsible for these 
differences.  Albeit an effect of the platelet washing procedure cannot be excluded. 
To further investigate platelet functional defects, we measured platelet aggregation 
and ATP secretion from dense granules, in response to select agonists by lumi-
aggregometry.  Moderate reductions in aggregation and ATP secretion were observed in 
G6b-B diY/F compared with WT platelets in response to 30 g/mL collagen, whilst platelets 
from G6b-B diY/F mice failed to respond to 30 g/mL CRP (Figure 4A, S7).  In contrast, 
G6b-B diY/F platelets, which exhibited a minor reduction in CLEC-2 expression, responded 
more rapidly to 3 g/mL anti-CLEC-2 antibody than WT platelets (Figure 4A, S7). No 
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difference was seen when platelets were stimulated with 3 nM of the tetravalent, CLEC-2 
binding snake toxin rhodocytin (Figure 4A and S5), which is a more robust agonist than the 
divalent anti-CLEC-2 antibody.  The amplitude of platelet aggregation was marginally 
reduced in G6b-B diY/F platelets in response to 0.06 U/mL thrombin and 10 M U46619, 
correlating with decreased ATP secretion (Figure 4A, S7).  Aggregation was also 
significantly reduced in response to 10 M ADP (Figure 4A, S7).  Taken together, these 
findings demonstrate moderate to severe impairments in platelet aggregation and ATP 
secretion to all agonists tested, except for anti-CLEC-2 antibody, which was enhanced. 
Integrin IIb3 activation and outside-in signaling were next interrogated by 
analyzing platelet adhesion and spreading on fibrinogen (Figure 4B).  The number of 
adhered platelets, platelet perimeter and surface area coverage of G6b-B diY/F platelets 
were normal compared with WT platelets, under basal conditions.  However, G6b-B diY/F 
platelets failed to maximally spread following pre-activation with 0.1 U/mL thrombin (Figure 
4Bi, ii), correlating with the reduced P-selectin exposure to thrombin described above 
(Figure 3Bi).  Morphological analysis of thrombin treated platelets revealed a significant 
increase in G6b-B diY/F platelets with filopodia and concomitant decrease in those forming 
lamellipodia, compared with WT platelets (Figure 4Bv), likely due to defective thrombin-
mediated platelet activation identified in aggregation studies. 
In light of these defects in platelet activation and function in response to specific 
agonists, a more physiologically relevant flow adhesion-based assay was performed to 
assess platelet recruitment to three surfaces: collagen; von Willebrand Factor binding 
peptide (vWF-BP) and laminin; and vWF-BP, laminin and rhodocytin (Figure 5).  Platelet 
adhesion to vWF-BP-laminin, via GPIb and the integrin 61, respectively, are important 
for initial platelet rolling and adhesion to exposed extracellular matrix.  A shear rate of 
1,000s-1 was chosen as a standard for phenotyping mice, to allow investigation of both 
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hemostasis and thrombosis.  Under almost all conditions tested G6b-B diY/F and G6b KO 
platelet adherence and thrombus formation were significantly reduced when quantifying 
morphological parameters and surface area coverage (Figure 5A, C).  Thrombus 
contraction and multilayer thrombus formation were also significantly reduced upon 
adhesion to collagen (Figure 5C), as were formation of procoagulant platelets, -granule 
release and integrin activation, measured by Annexin-V-647, anti-P-selectin-FITC and 
JON/A-PE antibody binding, respectively (Figure 5B, C).  Interestingly, G6b-B diY/F platelet 
IIb3 activation on vWF-BP-laminin-rhodocytin was unaltered, whilst it was reduced in 
G6b KO samples.  This could indicate a residual function of G6b-B, independent of Shp1 
and Shp2 interactions.  Previous studies using human blood showed an effect of low 
platelet counts on adhesion and activation in this assay, particularly on collagen-coated 
surfaces.16  The observed reductions are therefore at least partially due to 
thrombocytopenia in the loss-of-function and KO models.   
Collectively, evidence from the in vitro and ex vivo assays demonstrate that a 
combination of reduced platelet counts and defective activation responses produce the 
hemostatic defect observed in G6b-B diY/F mice (Figure 3A).  The combination of platelet 
defects is likely also responsible for the bleeding symptoms identified in G6b loss-of-
function patients (Hofmann et al, co-submitted). 
G6b-B inhibits CLEC-2 signaling via Shp2 
Since ITIM-containing receptors are most commonly characterized as negative regulators of 
ITAM-containing receptor signaling, we set out to determine at which stage G6b-B targets 
this pathway in platelets.  The increased aggregation response to anti-CLEC-2 antibody in 
G6b-B diY/F mice (Figure 4A) made this hemi-ITAM-containing receptor ideal for further 
investigation.  Washed platelets from G6b KO, G6b-B diY/F, Shp1 KO and Shp2 KO, and 
WT mice, were activated with 10 g/mL anti-CLEC-2 antibody for three minutes.  Key 
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proximal tyrosine phosphorylation signaling events were then assessed by western blotting 
(Figure 6).  As expected from aggregation studies (Figure 4A),6,12 platelets from G6b KO, 
G6b-B diY/F and Shp2 KO mice all exhibited increased whole cell tyrosine phosphorylation 
(p-Tyr) following antibody-mediated CLEC-2 stimulation, compared to WT platelets (Figure 
6A, B, C).  Platelets from the Shp1 KO mice did not (Figure 6D),12 suggesting G6b-B 
mediates an inhibitory effect on CLEC-2 signaling through Shp2 specifically.  Rhodocytin-
mediated tyrosine phosphorylation in G6b-B diY/F platelets was normal (Figure S8), 
correlating with the normal aggregation and ATP secretion responses (Figure 4A). 
Using phospho-specific antibodies, we investigated the site of action of G6b-B-Shp2 
on CLEC-2 signaling.  We focused on SFKs, which phosphorylate the tyrosine residue 
within the hemi-ITAM of the CLEC-2 receptor, and spleen tyrosine kinase (Syk), which 
binds the phosphorylated hemi-ITAMs of two adjacent CLEC-2 receptors and mediates 
downstream effects.  SFK activation was indirectly measured as trans-autophosphorylation 
of the highly conserved tyrosine residue 418 in Src (Src p-Tyr418) and Syk activation as 
trans-autophosphorylation of tyrosine residues 519/520 (p-Tyr519/20), both of which directly 
correlate with activity.  Following quantification, Src p-Tyr418 was not significantly altered in 
CLEC-2-stimulated platelets from all mouse models, whereas Syk p-Tyr519/520 was 
significantly higher in CLEC-2-stimulated G6b KO, G6b-B diY/F and Shp2 KO compared 
with WT and Shp1 KO platelets (Figure 6A-D).  It should be noted that co-migrating plasma 
proteins present in both G6b KO and G6b-B diY/F samples occasionally interfered with the 
migration and appearance of Syk blots.  This was controlled for when quantifying by 
normalizing Syk p-Tyr519/20 band intensities to total Syk band intensities for each sample.  
These findings suggest that G6b-B-Shp2 inhibits CLEC-2 signaling by directly 
dephosphorylating either CLEC-2, to abolish Syk association, and/or Syk, attenuating its 
activity. 
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Shp2 interacts directly with phosphorylated G6b-B in an extended orientation 
Since Shp2 appears to be the dominant mediator of G6b-B function in mouse platelets,12 
and the proteins are known to associate by co-immunoprecipitation and direct 
phosphopeptide binding experiments,6,10,17 we investigated the structural basis of their 
interaction in solution using heteronuclear magnetic resonance (NMR) spectroscopy.  
Recombinant N- and C-SH2 domains of Shp2 were incubated with phospho-peptides 
corresponding to the ITIM (p-ITIM) and ITSM (p-ITSM) of G6b-B.  This revealed that the N- 
and C-SH2 domains of Shp2 preferentially interact with p-ITIM and p-ITSM of G6b-B, 
respectively (Figure 7A, B).  The chemical shift perturbations between apo and bound forms 
of C-SH2 and p-ITSM exhibited slow exchange, indicating strong interactions.  This 
accounts for the increased affinity of the tandem SH2 domain for the dual p-ITIM and p-
ITSM peptide, over that seen with isolated N-SH2.17  The tandem SH2-phospho-peptide 
interaction showed comparable chemical shift perturbations, indicating synergistic binding 
of the doubly phosphorylated peptide to both SH2 domains (Figure 7C, D).  The direct 
interaction of Shp2 SH2 domains with G6b-B cognate binding motifs explains the critical 
role of the two residues mutated in the G6b-B diY/F mice reported here.  Moreover, the 
structural model of the complex is fully supported by earlier studies reporting the binding 
affinity to be 0.5 nM.17  The structural studies show that the Y/F substitutions would 
eliminate critical contacts that allow the deep, simultaneous insertion of G6b-B’s ITIM and 
ITSM phosphotyrosine residues into Shp2 N-SH2 and C-SH2 domains, respectively, in a 
manner that is consistent with canonical SH2 ligand binding modes.18  Moreover, the 
interaction with Shp2 tandem SH2 domains would also be compromised by G6b-B deletions 
and point mutations in Shp2, including L210I, R223H/C and A238V that have been found in 
human tumors,19-21 suggesting wider roles for Shp2 uncoupling in cancer. 
 
17 
 
Discussion 
This study establishes the physiological significance of tyrosine phosphorylation of the ITIM 
and ITSM domains of G6b-B in regulating platelet number and function.  Uncoupling of 
G6b-B from Shp1 and Shp2 leads to a severe platelet phenotype, closely resembling that 
observed in G6b-B-deficient mice and patients (Hofmann et al. co-submitted).6  The primary 
features of the G6b-B loss-of-function and KO phenotypes included severe 
macrothrombocytopenia due to reduced platelet production, large MK clusters and 
myelofibrosis at sites of hematopoiesis, down-regulation of the GPVI-FcR--chain complex 
and increased signaling through CLEC-2 in platelets.  Increased platelet activation via the 
CLEC-2 pathway was specifically due to Shp2 recruitment to G6b-B, which acted to inhibit 
the hemi-ITAM-Syk dependent pathway.  
 Minor differences in the phenotypes of G6b diY/F KI and KO mouse models may be 
due to residual functions of G6b-B diY/F, a dominant negative effect of this mutant form of 
the receptor or functional roles of splice isoforms of G6b-B, which have been hypothesized 
to exist.  Despite the apparent difference in bleeding between G6b-B diY/F KI and KO mice, 
this did not reach significance.  Potential incomplete penetrance of the G6b-B diY/F 
phenotype correlates with an identified null patient presenting with no clinical symptoms 
(Hofmann et al., co-submitted).  However, variability in humans beyond G6b mutations 
could explain the observed differences between patients. 
We previously reported a strong overlap between the phenotype of Shp1/2 DKO 
mice and G6b conditional KO (G6bfl/fl; Pf4-Cre+) mice.12  However, the phenotype of Shp1/2 
DKO mice was more severe than that of G6b conditional KO mice, including severe 
developmental defects in MKs that were not observed in G6b-B-deficient mice, reflecting 
other functional roles of Shp1 and Shp2.  Thus, the G6b-B diY/F KI mouse model provides 
a more refined approach to demonstrate that G6b-B signals exclusively through Shp1 and 
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Shp2.  This G6b-B loss-of-function mouse model also allows for expression of other splice 
isoforms of G6b-B.  This includes G6b-A-like, which is predicted to share the same 
extracellular, transmembrane and juxtamembrane regions as G6b-B, but has an entirely 
different cytoplasmic tail, lacking the ITIM and ITSM.  Although we have demonstrated 
expression of the G6b-A splice variant in human platelets, using a custom anti-G6b-A 
antibody (Hofmann et al. co-submitted), generation of an antibody specific to the mouse 
G6b-A-like protein has been unsuccessful.  This is due to lack of antigenic sites in the 
predicted mouse G6b-A-like protein.  The function of human G6b-A also remains unknown, 
but advances can now be made through the use of the custom antibody and humanized 
G6b mouse model described by Hofmann et al. (co-submitted). 
G6b-B appears to primarily signal through Shp2 in mice, as Shp2 KO mice more 
closely phenocopied G6b KO and G6b-B diY/F mice than Shp1 KO mice.12  This may be 
accounted for by the affinity of Shp2 for G6b-B being 100-fold greater than Shp1,17 and/or 
the relative stoichiometry of the two PTPs.  Shp2 is expressed at levels six-fold greater than 
Shp1 in mouse platelets,22 meaning in the absence of Shp1, the highly expressed Shp2 
may provide better compensation than vice versa.  Structural characterization of Shp2 
modular interaction with phospho-G6b-B-ITIM-ITSM peptides revealed simultaneous 
binding of its N-SH2 domain with the phospho-ITIM and its C-SH2 domain with the 
phospho-ITSM, resulting in a high affinity interaction that is dependent on the 
phosphotyrosines that were substituted in the knock-in mice.  This double mutation would 
compromise the complexed orientation that alleviates the intra-molecular interaction, 
between the backside of the N-SH2 domain of Shp2 and the PTP catalytic site, that 
normally allows activation of the phosphatase.11  Moreover, the double mutation would have 
prevented the high affinity, stable interaction with G6b-B that provides localization of Shp2 
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to the plasma membrane, with its PTP domain freely available for engagement with 
substrates, including phosphorylated CLEC-2 and/or Syk.   
 One of the main phenotypes of the G6b-B diY/F mouse is the severe 
macrothrombocytopenia, which was found to be due to reduced platelet production, and not 
increased clearance.  Comparison of the proportionate slopes of reduction in biotinylated 
platelets in circulation showed no significant difference with WT mice, which does not 
correlate with increased clearance of G6b KO platelets previously published.6  However, 
this most likely reflects the method of analysis, as the total platelet counts are not 
significantly different.  Reduced platelet counts are therefore due to decreased platelet 
production, supported by the reduced platelet recovery following depletion and observed 
extramedullary hematopoiesis.   
 Analysis of the regulation of ITAM-containing receptor signaling by G6b-B in the 
G6b-B diY/F mouse model is complicated by the reduced platelet counts and severe down-
regulation of the collagen receptor complex GPVI-FcR.  This down-regulation of GPVI-
FcR is thought to be due to loss of inhibition of Syk, by G6b-B recruited Shp1 and Shp2, 
activating negative feedback mechanisms, such as shedding.6  Both flow cytometric and 
lumi-aggregometry based assays showed reduced G6b-B diY/F response to GPVI-specific 
agonists.  The predicted increase in signaling in the absence of G6b-B-Shp1-Shp2 
interaction is therefore not sufficient to overcome the down-regulation of GPVI.   
In contrast, flow cytometry, aggregation and biochemical studies showed the 
expected hyper-reactivity of G6b-B diY/F platelets to CLEC-2-mediated hemi-ITAM 
signaling.  Similar increases in signaling were observed in G6b KO and Shp2 KO, but not in 
Shp1 KO mice.  Syk, and not SFK, activation was increased in these mice indicating Syk, 
and/or the CLEC-2 receptor itself, are the target of G6b-B-Shp2 phosphatase activity.  The 
pathophysiological consequences of increased CLEC-2 activity is presently not known and 
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cannot be ascertained using either the G6b KO or G6b diY/F mouse models due to the 
concomitant reductions in platelet counts and accompanying platelet anomalies.  Thus, 
other means of investigating effects of increased CLEC-2 signaling on vessel development, 
permeability and other physiological processes will have to be implemented. 
Other than in washed platelets stimulated with CLEC-2 antibody, P-selectin exposure 
was significantly reduced in response to all agonists.  Absence of -granule release rescue 
upon PAR4p and ADP co-stimulation indicate that defects are not due to loss of secondary 
signaling.23  Together with the reduced spreading, this suggests a positive regulatory role 
for G6b-B in regulating -granule release.  Interestingly, agonists that activate G protein-
coupled receptors (GPCRs) also showed attenuated aggregation responses in G6b-B diY/F 
mouse platelets.  This may indicate direct involvement of the G6b-B-Shp1-Shp2 signaling 
complex in regulation of GPCR-mediated tyrosine kinase signaling,24,25 or an indirect 
consequence of other platelet defects, including aberrant secretion or receptor turnover.  
The regulation of GPCR signaling by ITIM-containing receptors is highly provocative and 
warrants further investigation. 
 Despite Shp2 KO mice most closely resembling G6b KO and G6b-B diY/F 
phenotypes, some features do not overlap.12,13  Shp1 KO mice show normal platelet 
production, clearance and reactivity to most agonists.  However, the absence of Shp1 in 
platelets reduces GPVI surface expression, as observed in G6b-B diY/F platelets.  Platelets 
from both models are therefore hypo-responsive to GPVI-specific activation.  GPVI is 
known to be shed from the platelet surface once activated,26 indicating that loss of G6b-B-
Shp1 mediated inhibition causes activation of this negative feedback mechanism.   
 These findings confirm the hypothesis that the regulation of platelet homeostasis by 
G6b-B is dependent upon recruitment and signal transduction by the PTPs Shp1 and Shp2.  
Loss of this interaction severely impairs the formation of functional platelets that are 
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essential for the maintenance of hemostasis.  As GPVI and CLEC-2 share common 
downstream signaling proteins, it is of note that they are differentially regulated by Shp1 
and Shp2.12  Whether this is due to differences in compartmentalized recruitment of Shp1 
and Shp2 into proximity with GPVI and CLEC-2, which may be localized differentially in the 
plasma membrane, or differences in targeting of proteins specific to each pathway, remains 
to be determined.  
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Figure legends 
Figure 1.  Loss of ITIM/ITSM phosphorylation prevents G6b-B-Shp1-Shp2 interaction. 
(A) Flow cytometric and (B) western blot analysis of G6b-B expression in platelets from WT 
and G6b-B diY/F mice.  Mean ± SEM (n=6) of G6b-FITC median fluorescence intensity, 
with rat IgG2A subtracted.  Representative blots and quantification, normalized to tubulin 
reblots (mean ± SEM, n=3).  (C) Lysates were prepared using washed platelets (5 × 
108/mL) under basal and 30 g/mL collagen stimulated conditions (90 seconds, 37ºC, 
stirring at 1200 rpm) from WT and G6b-B diY/F mice.  Co-immunoprecipitation of Shp1 and 
Shp2 was investigated by western blotting, following immunoprecipitation using anti-G6b-B 
or non-immune rabbit polyclonal antibodies. 
Figure 2.  Uncoupling of G6b-B-Shp1-Shp2 disrupts platelet production 
(A) Percentage of reticulated platelets following staining with ReticCount, mean ± SEM 
(n=6), ***P < 0.001.  (B) Clearance of platelets in WT and G6b-B diY/F mice, following 
labelling with I.V. injected NHS-biotin.  Biotin labelled platelets measured by Streptavidin-
PE binding in tail vein-sampled whole blood, mean ± SEM, n=5-6 per data point.  Rate of 
platelet elimination calculated from slope of loss of biotinylated platelets, mean ± SEM, n=6.  
(C) Platelet recovery following anti-GPIb antibody mediated platelet depletion in WT and 
G6b-B diY/F mice (n=8-20 per time point).  Platelet recovery rate calculated from recovery 
data for WT and G6b-B diY/F mice between days 3 and 7, mean ± SEM, n=8-11, ***P < 
0.001.  (D) Representative images and quantification of the number of megakaryocytes in 
H&E stained spleen and femur sections from WT and G6b-B diY/F mice, mean ± SEM, n=6 
mice, 5 images per mouse, ***P < 0.001.  Yellow arrow heads indicated megakaryocytes.  
Representative images of reticulin staining showing myelofibrosis of WT and G6b-B diY/F 
spleens and femurs (scale bar: 50 m).  Spleen to body weight ratio in WT, G6b-B diY/F 
and G6b KO, mean ± SEM, n=22, ***P < 0.001. 
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Figure 3.  Aberrant platelet activation in G6b-B diY/F mice 
(A) Blood loss to body weight ratio following excision of 5 mm of tail tip in isofluorane 
anaesthetized mice of the indicated genotypes.  Data was analyzed using a bi-modal 
function, comprising of a gamma and normal distribution for low and high bleeding 
tendency, respectively.  Likelihood ratio tests were performed to determine whether the 
probability of bleeding (Pbleed) differed between genotypes.  (A, B, C, D) Flow cytometric 
measurement of P-selectin exposure and fibrinogen binding of WT and G6b-B diY/F 
platelets in whole blood using (A) Immunoreceptor tyrosine-based activation motif-activating 
and (B) G protein-coupled receptor-activating agonists, mean ± SEM, n=5-6 per stimulation.  
Thrombin stimulations were in the presence of 10 M GPRP to prevent blood clotting.  (C) 
Rescue of activating PAR4 peptide (PAR4p) stimulated fibrinogen binding in the presence 
of 10 M ADP, mean ± SEM, n=5-6.  Platelets were gated using forward- and side-scatter 
and 10,000 events collected. 
Figure 4.  Aberrant platelet function in G6b-B diY/F mice 
(A) Mean aggregation and ATP release traces in washed platelets (2 × 108/mL).  For ADP 
aggregations, platelets were washed in the presence of 0.02 U/mL apyrase and 
supplemented with 1 M CaCl2 and 50 g/mL fibrinogen.  Mean ± SEM, n=4-5.  (B) 
Representative images of WT and G6b-B diY/F washed platelet (2 × 107/mL) spreading on 
fibrinogen under basal and 0.1 U/mL thrombin preactivated conditions (scale bar: 5 m).  
Quantification of surface area coverage (***P < 0.001), platelet perimeter (n.s.), total 
platelets per image (n.s.) and four stages of spreading in the presence of thrombin (***P < 
0.001), mean ± SEM, n=5-6.   
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Figure 5.  Reduced platelet adhesion and activation under flow conditions. 
PPACK, heparin and fragmin anticoagulated whole blood from WT, G6b-B diY/F and G6b 
KO mice was flowed for 3.5 minutes, 1000 s-1 shear, over coverslips coated with collagen, 
von Willebrand Factor-binding protein (vWF-BP) + laminin and vWF-BP + laminin + 
rhodocytin.  (A) Representative brightfield images, (B) representative fluorescence images 
following staining with Alexa-647 conjugated annexin V, P-selectin-FITC and JON/A-PE 
antibodies to measure phosphatidylserine positive platelets, -granule release and IIb3 
integrin activation (IIb3act), respectively (scale bar: 10 m).  (C) Heatmap to show effect 
size of morphology scores and surface area coverage (SAC) of indicated parameters, 
normalized to WT (n=5-6). 
Figure 6.  G6b-B-Shp2 regulates CLEC-2 signaling. 
Washed platelets (4 × 108/mL) from (A) G6b KO, (B) G6b-B diY/F, (C) Shp1 KO and (D) 
Shp2 KO mice, and litter matched WT controls, were activated with 10 g/mL of activating 
CLEC-2 antibody in the presence of 10 M lotrafiban, before lysing and investigation of 
named phospho-tyrosine sites by western blotting. Representative western blots from three 
independent experiments. 
Figure 7.  Structural basis of G6b-B recognition by SHP2  
The specific interactions are shown by comparison of (A) N-SH2 apo (black) and N-SH2 + 1 
equivalent pITIM (sky blue) (B) C-SH2 apo (black) and C-SH2 + 1 equivalent pITSM (red) 
and (C) tandem SH2 apo (teal) and tandem SH2 + 1 equivalent pITIM+pITSM (red).  
Selected chemical shift perturbations in SOFAST-HMQC NMR spectra are labeled.  (D) 
Lowest energy model of tandem SH2 bound to pITIM+pITSM generated by HADDOCK 
based on restraints generated from the NMR data.  Residues showing large chemical shift 
perturbations are shown in blue and are defined as active residues directly involved in 
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interaction with the peptide.  Residues showing small yet significant chemical shift 
perturbations are shown in cyan and are defined as passively involved residues. 
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Supplementary Methods 
Generation of G6b-B diY/F mice 
A constitutive knock-in (KI) strategy was used to generate G6b-B diY/F KI mice 
(Figure S1).  A targeting vector containing the mutated G6b gene and a puromycin 
resistance cassette (PuroR) flanked with flippase recognition target (FRT) sites was 
produced.  Point mutations were inserted into the G6b gene, converting the tyrosine 
codons TAC and TAT of exon 6 (positions 648 and 726 within the transcript 
nucleotide sequence, taken from NM_001191012.1) to TTC, the codon for 
phenylalanine.  Neighboring genes were also cloned into the targeting vector, 
providing 7 kb and 4 kb homology arms.  These allow for insertion of the mutant 
gene, via homologous recombination, into germline competent C57Bl6/NTac 
embryonic stem cells.  This effectively knocks out the WT G6b gene and replaces it 
with the mutant gene, called G6b-B diY/F.  Recombined mutants with the correctly 
inserted mutant construct were isolated using the PuroR gene positive- and 
thymadine kinase negative-selection.  Following validation, clones were injected into 
mouse blastocysts and transferred into pseudopregnant female mice.  G6b-B diY/F 
mice were subsequently crossed with Tg(CAG-flpe) Flp recombinase expressing 
mice, causing excision of the FRT sites, therefore removing the PuroR cassette and 
generating the final G6b-B diY/F constitutive KI mouse allele.  Further crossing with 
C57Bl6/NTac mice and selective breeding removed expression of Flp recombinase 
in animals used for experiments.   
Successful targeted KI was shown by PCR using oligos 1 & 2 and 5 & 6. 
The residual FRT site following excision of the PuroR gene allows for the WT and KI 
alleles to be distinguished by PCR.  Primers were generated to target the annealing 
sites indicated by oligos 3 and 4 (Figure 3.1Aiv).  These produce a PCR product of 
315 base pairs (bp) for the WT allele and 401 bp for the KI allele, which can be 
distinguished by running the PCR.   
Mouse G6b-specific antibodies 
The anti-mouse monoclonal antibody was raised by injection of Fc-fused G6b-B 
ectodomain into rats.  As such, this antibody will recognize both G6b-A-like and G6b-
B isoforms on the surface of platelets.  Anti-mouse G6b-B polyclonal antibody was 
generated by injection of a peptide specific to G6b-B into rabbits.  These were 
generated as previously described.1 
Platelet clearance 
Mice were injected intravenously with 600 g of N-hydroxysuccinimidobiotin (NHS)-
Biotin in PBS.  Blood samples were collected from tail veins, into 5 mM EDTA, 10% 
fetal bovine serum in PBS, at the following time points following injection: 1 hour (h) 
(Day 1), 24h (Day 2), 48h (Day 3), 72h (Day 4) and 96h (Day 5).  Percentage of 
biotin positive platelets was measured by flow cytometry using PE-Streptavidin (BD 
Pharmingen, Oxford, UK). 
Platelet recovery 
Platelets were depleted by intraperitoneal (I.P.) injection of 1.5 g anti-GPIb 
antibody (Emfret Analytics, Wurzburg, Germany) per gram of mouse body weight.  
Blood samples were collected from the tail vein into 20 mM EDTA in PBS before I.P. 
injection (Day 0) and at 24 hour intervals following this.  Platelet counts were 
measured using an ABX Pentra 60 hematological counter (Horiba Medical, 
Northampton, UK).  
 
Platelet clearance and recovery analysis 
Proportionate slopes were calculated for each mouse using data from days one to 
five and days two to seven for platelet clearance and recovery assays, respectively.  
These slopes were taken as a measurement of rate of platelet clearance (% of 
platelets per day) and rate of platelet production (× 108/mL platelets per day).   
Immunohistochemistry 
Spleens and femurs from G6b-B diY/F and WT mice were fixed in buffered formalin 
and embedded in paraffin.  Sections were H&E and reticulin stained and examined 
by light microscopy with a Zeiss Axio ScanZ1 (Carl Zeiss Ltd, Cambridge, UK). 
Tail bleeding assay 
Mice were anaesthetized using isoflurane and placed on a raised heating pad at 
37°C.  5 mm of the tail tip was excised using a scalpel blade and blood drops 
collected (falling in air) to a maximum time of 20 minutes, or 5 minutes with no blood 
drop falling.  Bleeding tendency was quantified by determining the mass of blood 
loss (mg) following injury and dividing by the weight of the mouse (g).  A maximum 
allowed blood loss was calculated for each mouse equal to ≤10% of body weight.  
Blood loss for all animals remained within this limit.  Where the blood loss was 
recorded as zero (n=1) a value equal to the average of zero and 50% of the limit of 
detection (0.1 mg blood loss) was employed.   
Blood loss (mg/g) was modelled as a bi-modal function, comprising of a gamma 
distribution representing a low (normal) bleeding tendency and a normal distribution 
representing increased bleeding.  The probability that a mouse of a specified 
genotype had a normal bleeding time was Pnorm or was a bleeder was (1 – Pnorm).  
Probabilities were modelled as logits. (logit(P) = ln(P/(1-P)) ) 
The maximum likelihood (-2LL = -2 × log likelihood) was determined generating 
parameters that defined normal and increased bleeding and the logits of the 
probabilities of each genotype having normal bleeding.  Likelihood ratio tests were 
performed to determine whether the probability of bleeding differed between 
genotypes. 
Modelling was done in Microsoft Excel (Redmond, WA, USA) and replicated in 
NONMEM 7.3 (Icon PLC, Dublin, Ireland) to generate standard error values for the 
parameters. 
Flow cytometry 
Mice were CO2-asphyxiated and blood collected from the vena cava into 1/10 (v/v) 
acid-citrate-dextrose anticoagulant.  Fluorescein isothiocyanate (FITC)-conjugated 
antibodies were used to measure surface receptor expression in whole blood with an 
Accuri C6 flow cytometer (BD Biosciences, Oxford, UK).  Values for relevant IgG 
controls have been subtracted from all presented data.  For flow cytometry based 
activation assays, whole blood or 2 × 107/mL washed platelets were stained with 
FITC-conjugated P-selectin antibody or Alexa488-conjugated fibrinogen in the 
absence (basal) and presence of indicated agonists.  Thrombin stimulations were 
performed in the presence of 10 M GPRP to prevent fibrin polymerization.  For all 
flow cytometry 10,000 events were collected and data is presented as median 
fluorescence intensity.  Reactions were terminated with cold 1% paraformaldehyde 
in PBS.  The proportion of reticulated platelets in whole blood was quantified by flow 
cytometry following 30 minute incubation with BD Retic-Count solution (BD 
Biosciences, Oxford, UK).   
 
Platelet adhesion and spreading on fibrinogen 
Washed platelets (2 × 107/mL) were prepared as previously described in modified 
Tyrodes buffer (134 mM NaCl, 2.9 mM KCl, 340 M Na2HPO4•12H2O, 12 mM 
NaHCO3, 20 mM HEPES, 1 mM MgCl2, 5 mM glucose, pH 7.3, 37°C).2  Platelet 
spreading assay on fibrinogen-coated coverslips was performed as previously 
described.3  All slides were imaged using a Zeiss Axiovert 200M microscope and 
quantified using ImageJ.  Stages of platelet spreading were categorized as 
unspread, formation of filopodia, formation of lamellipodia and fully spread (Figure 
S6). 
Platelet aggregation and secretion 
Platelet aggregation and adenosine triphosphate (ATP) secretion was measured in 
washed platelets (2 × 108/mL) using a Chrono-Log Model 700 lumi-aggregometer 
(Havertown, PA, USA), as previously described.4  ADP-sensitive platelets were 
prepared as previously described,5 using modified Tyrodes buffer supplemented with 
0.02 U/mL apyrase for washing steps.  The final platelet pellet was resuspended in 
modified Tyrodes buffer without apyrase and before starting aggregations 1 M 
CaCl2 and 50 g/mL fibrinogen was added to the diluted platelets.  Aggregation 
traces were exported and mean traces calculated. 
Platelet flow adhesion coverslip preparation 
Glass coverslips (24 × 60 mm) were coated with three microspots (0.5 L/spot), 
which produce thrombi via different platelet-adhesive receptors (De Witt, Nat Comm 
2014).  The microspot coatings contained (in the direction of flow): (i) von Willebrand 
factor-binding peptide (VWF-BP, 12.5 mg/mL, purified as described in Lisman, Blood 
2006) + laminin (50 g/mL, from human plasma); (ii) VWF-BP + laminin + rhodocytin 
(250 g/mL, from BioSource and purified as described in Hooley, Biochemistry 
2008); (iii) collagen type I (100 µg/mL, Nycomed Pharma, Munich, Germany).  The 
coated coverslips were blocked with modified Tyrode’s Hepes buffer pH 7.45 (TH-
buffer: 5 mM Hepes, 136 mM NaCl, 2.7 mM KCl, 2 mM MgCl2, 0.42 mM NaH2PO4) 
containing 1% bovine serum albumin and mounted into parallel plate flow chambers.   
Platelet flow adhesion  
Blood was collected as above into 40 M PPACK, 5 units (U)/mL heparin and 50 
U/mL fragmin (final concentrations) and perfused for 3.5 minutes, at a wall-shear 
rate of 1000 s-1, over glass coverslips coated with microspots of indicated platelet 
agonists.6  Images were captured with an EVOS microscope (Life Technologies, 
Carlsbad, CA, USA) and analyzed using Fiji (Figure S7).7 
Platelet flow adhesion image capture and analysis 
Immediately after perfusion of blood was complete, brightfield images were captured 
from each microspot.  Thrombi were then stained using TH-buffer containing 1 
mg/mL glucose and 1 mg/mL bovine serum albumin, supplemented with 2 mM 
CaCl2, 1 U/mL heparin, Alexa647-conjugated annexin A5 (1:200, Invitrogen Life 
Technologies, Carlsbad, CA, USA), FITC-conjugated anti-P-selectin antibody (1:40) 
and PE-conjugated anti-JON/A antibody (1:20).  Per microspot, 2 (brightfield) or 3 
(fluorescence) representative images were taken and analyzed.   
Recorded images were analyzed using semi-automated scripts written in Fiji 
software (Laboratory for Optical and Computational Instrumentation at the University 
of Wisconsin-Madison, USA).  This resulted in percentages of surface area coverage 
(%SAC) of deposited platelets/thrombus (from brightfield images), and of %SAC of 
platelet/thrombus fluorescence per fluorescent label.  In addition, brightfield images 
were analyzed for a morphological score (scale 0-5), thrombus contraction score 
(scale 0-3) and thrombus height (multilayer, scale 0-3) in comparison to reference 
images, to provide an indication of the overall size and height of platelet aggregates 
on the microspots (Figure S7, De Witt, Nat Comm 2014).  Finally, the %SAC of 
multilayered thrombi was analyzed by manual coloring in Fiji. 
Platelet biochemistry 
All stimulations were conducted in the presence of 10 M lotrafiban, 37°C with 
constant stirring at 1,200 rpm.  Whole cell lysates were prepared, 
immunoprecipitations performed and resolved by SDS-PAGE, as previously 
described,8 using washed platelets at 4-5 × 108/mL.  Band intensities were quantified 
using ImageJ and normalized to reblots of either pan-Syk or tubulin as stated in 
Figure Legends. 
Protein production for structural analysis of G6b-B-Shp2 interaction 
Human G6b-B p-ITIM (residues 206-215; EPSLL[pY]ADLD), p-ITSM (residues 232-
241; DASTI[pY]AVVV) and dual p-ITIM/p-ITSM (residues 206-241; EPSLL 
[pY]ADLDHLALSRPRRLSTADPADASTI[pY]AVVV) peptides were synthesized by 
Alta Bioscience (Birmingham, UK) or Genscript (NJ, USA).  All peptides were N-
terminally acetylated, while only p-ITIM was C-terminally amidated.  The individual 
human SH2 domain constructs were provided by Tony Pawson (University of 
Toronto).  The tandem SH2 domain construct containing residues 4-216 of wild-type 
Shp2, preceded by a TEV protease cleavable poly-histidine tag, was inserted into a 
pNIC28-Bsa4 vector obtained from SGC (Oxford, UK) by ligation independent 
cloning.  Proteins were expressed in E. coli using minimal M9 media with 15NH4Cl as 
the sole nitrogen source and, for assignment purposes, uniformly labeled 13C-
glucose as the sole carbon source.  Proteins were purified using Ni-NTA affinity 
columns followed by size exclusion chromatography. 
Structural analysis of G6b-B-Shp2 interaction 
NMR spectroscopy was performed at 25°C using a 600 MHz Varian Direct Drive 
spectrometer for the individual SH2 domains and an 800 MHz Varian Inova 
spectrometer for the tandem SH2 constructs.  Protein concentrations for all titrations 
were 400 µM.  Spectra were processed using NMRpipe,9 and analyzed using CCPN 
analysis.10  Model structures of tandem SH2 binding to the phosphorylated C-
terminal tail of G6b-B were generated using HADDOCK.11,12 
For residue-specific NMR assignments either BEST (Lescop et al. 2007) (for the 
individual SH2 domains) or standard versions (for the tandem SH2) of HNCOCA, 
HNCA, HNCO, HNCACO, HNCACB and HNCOCACB spectra were obtained.  
Titration data were collected using SOFAST-HMQC experiments (Schanda et al. 
2005). 
For model structures the pdb file 5DF6 (Liu at al. 2016) was used as the template for 
the protein structure.  Binding of the peptide to the protein was assumed to be 
canonical with respect to the pY pocket.  Distance restraints of 7Å between R128-
CZ: pY237-P and R32-CZ:pY211-P were used to orientate the peptide with nSH2 
binding to ITIM and cSH2 binding to ITSM.  Peptide residues outside the canonical 
SH2 domain recognition site (pY, +1, +3) were allowed to be fully flexible during the 
HADDOCK calculation as were the residues linking the two SH2 domains (102-110).  
Initial peptide complex structure generation and model visualization was performed 
using PyMOL (Schrödinger, Cambridge, UK). 
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Genotype Expected
frequency
Observed
frequency
WT (G6b+/+) 25% (60) 29% (70)
Heterozygous 
(G6b+/diYF)
50% (121) 46% (111)
Homozygous 
(G6bdiYF/diYF)
25% (60) 25% (60)
Total 100% (241) 100% (241)
Table S1.  Offspring from het  het breeding pairs
Table S2.  Peripheral blood cell counts
Haematological 
parameters
WT
(mean ± SD, n=24)
G6b-B diY/F
(mean ± SD, n=24)
Platelets (109/L) 1093 ± 230 258 ± 64***
Mean platelet volume (fL) 5.8 ± 0.2 7.9 ± 1.8***
Plateletcrit (%) 0.41 ± 0.10 0.10 ±0.06***
Red blood cells (1012/L) 10.9 ± 0.6 10.4 ± 1.1
Hematocrit (%) 31.8 ± 2.6 29.4 ± 3.7*
White blood cells (109/L) 8.3 ± 4.6 9.8 ± 4.3
Lymphocytes (109/L) 5.5 ± 3.4 12.5 ± 4.6***
Monocytes (109/L) 0.70 ± 0.60 0.90 ± 0.60
Neutrophils (109/L) 0.65 ± 0.45 1.10 ± 0.76*
Eosinophils (109/L) 0.01 ± 0.04 0.00  ± 0.04
Basophils (109/L) 0.39 ± 1.39 0.10 ± 0.27
Data was collected from 13 breeding pairs (G6b+/diYF
× G6b+/diYF) and analysed using χ2 test (P = 0.2875)
* indicates P<0.05 and *** indicates P<0.001 with Students t-test
Figure S1. Targeting strategy for constitutive knock-in of G6b-B diY/F allele. A
constitutive knock-in strategy was used by Taconic to insert a mutated G6b allele into (A) the
genomic locus of mouse G6b. (B) A targeting vector containing point mutations within exon
6 and a puromycin resistance cassette flanked by Flp recombinase sites was produced. (C)
The two homology arms of the targeting vector flanking the mutated exon 6 provided sites
for homologous recombination to insert the mutated gene into the C57BL/6NTac embryonic
stem cell genome. (D) The puromycin resistance was removed by crossing mice expressing
the G6b-B diY/F allele with a Flpe recombinase expressing mouse producing the final
constitutive knock-in allele.
G6b exon G6b untranslated region Mutated G6b exon Neighbouring gene
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Figure S2. Interaction of G6b-B with Shp1 and Shp2. (A) Immunoprecipitation of G6b-B in
WT and Shp2 KO mouse washed platelets (4 × 108/mL) was performed to investigate the
specificity of Shp1 and Shp2 antibodies. (B) Specificity of Shp1 and Shp2 antibodies were also
investigated in whole cell lysates from WT, Shp1 KO and Shp2 KO mouse platelets. (C) Basal
and 30 mg/mL collagen activated platelets were lysed and Shp2 immunoprecipitated to
investigate the co-immunoprecipitation of G6b-B. Representative blots from two independent
experiments.
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Figure S3. Blood cell counts variation is independent of age in G6b-B diY/F mice. (A)
Blood cell counts were plotted against age for G6b-B diY/F mice (n=24). (B) Regression
analysis indicates that there is no correlation between age and hematological parameters.
P
la
te
le
t 
co
u
n
t
P
la
te
le
t 
vo
lu
m
e
P
la
te
le
tc
ri
t
R
ed
 b
lo
o
d
 c
el
ls
H
em
at
o
cr
it
Ly
m
p
h
o
cy
te
s
M
o
n
o
cy
te
s
N
eu
tr
o
p
h
ils
Eo
si
n
o
p
h
ils
B
as
o
p
h
ils
R2 0.00 0.00 0.01 0.09 0.08 0.07 0.21 0.12 0.13 0.02
P-value 0.80 0.13 0.63 0.15 0.18 0.22 0.02 0.10 0.09 0.49
a2 aIIb CLEC-2
Figure S4.  Quantification of surface receptor expression.  (A)  Median fluorescence 
intensity (mean ± SEM, n=5-6, * P<0.05, *** P<0.001).  (B) Representative histograms. IgG 
control (dark grey) and respective staining (light grey).
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Figure S5.  Total protein expression levels.  Lysates were prepared 
from washed platelets (4 × 108/mL).
Figure S6.  P-selectin exposure and fibrinogen binding in washed platelets.  (A) anti-P-
selectin-FITC and (B) fibrinogen-488 binding to washed platelets (2 × 107/mL) following 
stimulation with the indicated agonists.  Mean ± SEM, n=5,  ** P<0.01, *** P<0.0001.
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Figure S7. Analysis of aggregation and ATP release. Washed platelets (2 × 108/mL) were
activated with the indicated agonists in a lumi-aggregometer. For ADP stimulations platelets
were washed in the presence of 0.02 U/mL apyrase and once prepared supplemented with 1
mM CaCl2 and 50 mg/ml fibrinogen. Area under the curve (AUC) of aggregation and ATP
release was analysed, mean ± SEM, n=3-5, ** P<0.01, *** P<0.0001.
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Figure S8. Rhodocytin signalling in G6b-B diY/F, G6b KO and Shp2 KO mouse platelets. Washed platelets (4 ×
108/mL) from indicated genotypes were activated with 300 nM rhodocyin, 3 minutes, 10 mM lotrafiban, 37ºC, 1200 rpm
stirring. Stimulations were terminated by lysing cells and proteins were resolved by SDS-PAGE to investigate signalling
events using the inidicated phospho-specific antibodies. Src p-Tyr418 and Syk p-Tyr519/20 were quantified using ImageJ.
Representative blots from n=3-4.
Figure S9.  Platelet spreading on fibrinogen scoring categories
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Figure S10.  Platelet flow adhesion morphological scoring representative images
Morphological score: 0
Contraction score: 0
Multilayer score: 0
Morphological score: 3
Contraction score: 1
Multilayer score: 1
Morphological score: 1
Contraction score: 0
Multilayer score: 0
Morphological score: 4
Contraction score: 2
Multilayer score: 2
Morphological score: 2
Contraction score: 0
Multilayer score: 0
Morphological score: 5
Contraction score: 3
Multilayer score: 3
